Redx to resume clinical evaluation of RXC004 in patients with advanced solid tumours in the first half of 2019

Redx got back on track to resume clinical evaluation of RXC004 in patients with advanced solid tumours in the first half of 2019.

The company said Monday it got formal formal approval from UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to its restart of the phase 1/2a trial for porcupine inhibitor RXC004, targeting the Wnt signalling pathway.

Redx believes that the desired systemic exposure can be achieved using a significantly lower starting dose with the potential for clinical benefit.

Natalie Cook, Consultant Oncologist and Principal Investigator from the Christie Hospital in Manchester, UK said: “We have learnt a significant amount from the first patient treated with RXC004, and this provides the basis for an optimised RXC004 development plan as well as the confidence to evaluate the clinical potential of RXC004 in cancer patients.”

Lisa Anson, Chief Executive Officer, Redx Pharma said: “We believe that the revised RXC004 clinical protocol and development plan has the potential to offer clinical benefit both as a monotherapy and in combination with standard of care treatments. We look forward to working closely with our expert clinical oncology colleagues across the U.K. on this exciting programme.”